This study investigates the treatment of peritoneal metastatic pancreatic cancer. It focuses on the use of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy.
The study evaluates the safety and effectiveness of this combined treatment approach. It checks if this method improves survival rates and assesses its safety profile.
- Who can participate: Adults aged 18 to 80 years with confirmed peritoneal metastasis may participate. They must have no prior anti-tumor therapy and meet specific health criteria.
- Study details: Participants will receive heated chemotherapy administered directly into the abdomen and intravenous chemotherapy. An inactive substance that looks like the investigational medicine but does not contain any medicine is called a placebo.